A.R.T. Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

A.R.T. Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,238	Closed	-$1.83M	–	1098
2019 Q4	$1.83M	Buy	14,238 +10,200	+253%	+$984K	0.09%	324
2019 Q3	$315K	Sell	4,038 -1,700	-30%	-$160K	0.02%	1029
2019 Q2	$591K	Buy	+5,738	New	+$447K	0.03%	677
2018 Q4	–	Sell	-9,472	Closed	-$446K	–	1748
2018 Q3	$446K	Sell	9,472 -18,996	-67%	-$1.06M	0.02%	903
2018 Q2	$1.4M	Buy	+28,468	New	+$1.08M	0.06%	489
2016 Q3	–	Sell	-11,852	Closed	-$64K	–	1248
2016 Q2	$64K	Buy	+11,852	New	+$189K	﹤0.01%	1255
2014 Q3	–	Sell	-10,931	Closed	-$218K	–	1580
2014 Q2	$218K	Buy	+10,931	New	+$211K	0.01%	1097

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

A.R.T. Advisors's MRTX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 14,238 shares — an estimated $1.83M sold.

A.R.T. Advisors first reported a position in MRTX in Q2 2014 and held it in 7 quarters. The position peaked at $1.83M in Q4 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

A.R.T. Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 14,238 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.83M.
A.R.T. Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 7 quarters.
A.R.T. Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $1.83M in Q4 2019.
173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.